Summary

The GSA point-of-care-testing (POCT) market is expected to reach USD 9.07 billion by 2032 from USD 3.63 billion in 2024, growing at a substantial CAGR of 12.1% in the forecast period of 2025 to 2032.
Market Segmentation:
GSA Point-Of-Care-Testing (POCT) Market, By Product Type (Glucose Monitoring Products, Infectious Disease Testing Products, Cardiometabolic Monitoring Products, Pregnancy and Fertility Testing Products, Hematology Testing Products ,Coagulation Monitoring Products, Drugs-Of-Abuse (DOA) Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Tumor/Cancer Marker Testing Products, Fecal Occult Testing Products, and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Immunoassays, Dipsticks, Molecular Diagnostics, Clinical Chemistry Assays, Microfluidics, Hematology, and Others), Application (Blood Glucose, Infectious Diseases, Vital Sign Monitoring, Cardiac Monitoring, Coagulation, Haematology, Non- Invasive SpO2 Monitoring, Blood Transfusion, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, and Others), Prescription Mode (Prescription-Based Testing and Over The Counter Testing), End User (Hospitals, Home Care, Clinics, Laboratories, Diagnostic Centers, Pathology Labs, Ambulatory Surgery Centers, Elderly Care Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales, and Others), Country (Germany, Switzerland, Austria) - Industry Trends & Forecast To 2032
Overview of the GSA Point-of-Care-Testing (POCT) Market are:

Driver

• Rising Use of POC Testing in Healthcare Facilities

Restraint

• Data Security and Privacy Concerns
Opportunity

• Rising Awareness and Advocacy for Point-Of-Care Testing

Market Players:

Some of the major players operating in the GSA point-of-care-testing (POCT) market are:

• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• BIOMÉRIEUX
• BD (Becton, Dickinson and Company)
• QuidelOrtho Corporation
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Werfen
• QIAGEN
• Sysmex Europe SE
• EKF Diagnostics Holdings plc.
• SEKISUI Diagnostics
• MERIDIAN BIOSCIENCE
• binx health, inc.
• Trinity Biotech
• Sienco, Inc.
• ACCUBIOTECH CO., LTD.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE GSA AND BENELUX POINT-OF-CARE-TESTING (POCT) MARKET 55
1.4 LIMITATIONS 57
1.5 MARKETS COVERED 57
2 MARKET SEGMENTATION 61
2.1 MARKETS COVERED 61
2.2 YEARS CONSIDERED FOR THE STUDY 62
2.3 CURRENCY AND PRICING 62
2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
2.5 MULTIVARIATE MODELLING 68
2.6 PRODUCT TYPE LIFELINE CURVE 69
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 70
2.8 DBMR MARKET POSITION GRID 71
2.9 MARKET END USER COVERAGE GRID 73
2.10 SECONDARY SOURCES 74
2.11 ASSUMPTIONS 74
3 EXECUTIVE SUMMARY 75
4 PREMIUM INSIGHTS 83
4.1 PESTAL ANALYSIS 85
4.2 PORTERS FIVE FORCES ANALYSIS 86
4.3 MICRO AND MACRO ECONOMIC FACTORS 87
4.4 PENETRATION AND GROWTH PROSPECT MAPPING 87
4.5 KEY PRICING STRATEGIES 87
4.6 COST ANALYSIS BREAKDOWN 88
4.7 OPPORTUNITY MAP ANALYSIS 88
4.8 VALUE CHAIN ANALYSIS 89
4.9 HEALTHCARE ECONOMY 89
4.10 TARIFFS 90
4.10.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 90
4.10.2 GLOBAL VS. REGIONAL TARIFF STRUCTURES 90
4.10.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 90
4.10.4 TARIFF REGULATIONS IN KEY MARKETS 90
4.10.4.1 MEDICARE/MEDICAID TARIFF POLICIES 90
4.10.4.2 CMS PRICING MODELS 91
4.10.4.3 OTHERS 91
4.10.5 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 91
4.10.5.1 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 91
4.10.5.2 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 91
4.10.5.3 CASE STUDIES OF TARIFF CHANGES AFFECTING THE INDUSTRY 92
4.10.6 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 92
4.10.7 TARIFF EXEMPTIONS AND INCENTIVES 92
4.10.8 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 92
4.10.9 16.9 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 92
4.10.10 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 93
5 CUSTOMIZATION 94
5.1 LEADING DIGITAL HEALTH PLATFORMS IN EACH COUNTRY – 94
5.2 POCT DATA INTEGRATION USE CASES – 96
5.3 INFORMATICS PLATFORMS & TELEMEDICINE INTEGRATION: 97
6 REGULATORY 102
6.1 REGULATORY GSA 102
6.2 REGULATORY BENELUX 108
7 MARKET OVERVIEW 114
7.1 DRIVERS 116
7.1.1 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES 116
7.1.2 RISING INCIDENCE OF SUBSTANCE ABUSE 117
7.1.3 INCREASED ADOPTION OF TELEMEDICINE 119
7.1.4 ADVANCEMENTS TECHNOLOGIES ENHANCING POC TESTING WITH BIOSENSORS AND MOBILE INTEGRATION 120
7.2 RESTRAINTS 121
7.2.1 DATA SECURITY AND PRIVACY CONCERNS 121
7.2.2 ACCURACY LIMITATIONS AND TECHNICAL BARRIERS 122
7.3 OPPORTUNITIES 123
7.3.1 RISING AWARENESS AND ADVOCACY FOR POINT-OF-CARE TESTING 123
7.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS 123
7.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE TESTING 124
7.4 CHALLENGES 126
7.4.1 LIMITED AWARENESS AND ACCEPTANCE OF POINT-OF-CARE (POC) TESTING 126
7.4.2 IMPACT OF HIGH MAINTENANCE COSTS THREATEN POINT-OF-CARE TESTING (POCT) SUSTAINABILITY IN LOW-RESOURCE SETTINGS 126
 
8 GSA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE 128
8.1 OVERVIEW 129
8.2 GLUCOSE MONITORING PRODUCTS 134
8.2.1 STRIPS 135
8.2.2 METERS 135
8.2.3 LANCETS AND LANCING DEVICES 135
8.3 INFECTIOUS DISEASE TESTING PRODUCTS 136
8.3.1 COVID-19 137
8.3.2 HIV TESTING PRODUCTS 138
8.3.2.1 TESTING REAGENTS 138
8.3.2.2 TESTING EQUIPMENT 138
8.3.3 RESPIRATORY INFECTION TESTING PRODUCTS 139
8.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING 139
8.3.4.1 NAAT-BASED SYSTEMS 139
8.3.4.2 NON–NAAT-BASED SYSTEMS 139
8.3.5 HEPATITIS C TESTING PRODUCTS 140
8.3.5.1 HCV ANTIBODY TESTS 140
8.3.5.2 HCV VIRAL LOAD TESTS 140
8.3.6 INFLUENZA TESTING PRODUCTS 141
8.3.6.1 TRADITIONAL DIAGNOSTIC TEST 141
8.3.6.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) 142
8.3.6.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT) 142
8.3.6.1.3 VIRAL CULTURE 142
8.3.6.1.4 SEROLOGICAL ASSAY 142
8.3.6.2 MOLECULAR DIAGNOSTIC ASSAY 143
8.3.6.2.1 RT-PCR 144
8.3.6.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP) 144
8.3.6.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT) 144
8.3.6.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA) 144
8.3.7 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING 144
8.3.8 TROPICAL DISEASE TESTING PRODUCTS 144
8.3.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 144
 
8.4 CARDIOMETABOLIC MONITORING PRODUCTS 145
8.4.1 CARDIAC MARKER TESTING PRODUCTS 146
8.4.1.1 HSTNL 147
8.4.1.2 BNP 147
8.4.1.3 D-DIMER 147
8.4.1.4 CK-MB 147
8.4.1.5 MYOGLOBIN 147
8.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 147
8.4.3 BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES 148
8.4.3.1 CARTRIDGES 148
8.4.3.2 REAGENTS 148
8.4.4 BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS 149
8.4.4.1 PORTABLE 149
8.4.4.1.1 COMBINED ANALYZERS 150
8.4.4.1.2 BLOOD GAS ANALYZERS 150
8.4.4.1.3 ELECTROLYTE ANALYZERS 150
8.4.4.2 BENCHTOP 150
8.4.4.2.1 COMBINED ANALYZERS 151
8.4.4.2.2 BLOOD GAS ANALYZERS 151
8.4.4.2.3 ELECTROLYTE ANALYZERS 151
8.4.5 HBA1C TESTING PRODUCTS 151
8.4.5.1 HBA1C TESTING INSTRUMENTS 152
8.4.5.2 HBA1C TESTING CONSUMABLES 152
8.4.6 POC ANALYZER 152
8.4.7 ECG DEVICE 152
8.4.7.1 RESTING ECG DEVICES 153
8.4.7.2 STRESS ECG DEVICES 153
8.4.7.3 HOLTER MONITORS 153
8.5 PREGNANCY AND FERTILITY TESTING PRODUCTS 154
8.5.1 PREGNANCY TESTING PRODUCTS 154
8.5.1.1 STRIPS/ DIP STICKS AND CARDS 155
8.5.1.2 MID STREAM DEVICES 155
8.5.1.3 CASSETTES 155
8.5.1.4 DIGITAL DEVICES 155
8.5.1.5 LINE-INDICATOR DEVICES 155
8.5.2 FERTILITY TESTING PRODUCTS 156
8.5.2.1 LUTEINIZING HORMONE (LH) URINE TEST 156
8.5.2.2 FSH TEST 156
8.5.2.3 OTHERS 156
 
8.6 HAEMATOLOGY TESTING PRODUCTS 157
8.7 COAGULATION MONITORING PRODUCTS 157
8.7.1 ANTICOAGULATION MONITORING DEVICES 158
8.7.1.1 PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES 159
8.7.1.2 ACTIVATED CLOTTING TIME (ACT) 159
8.7.1.3 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT) 159
8.7.2 PLATELET FUNCTION MONITORING DEVICES 159
8.7.3 VISCOELASTIC COAGULATION MONITORING DEVICES 159
8.7.3.1 ROTATIONAL THROMBOELASTOMETRY (ROTEM) 159
8.7.3.2 THROMBOELASTOGRAPHY (TEG) 159
8.8 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS 160
8.8.1 DOA ANALYSERS 160
8.8.1.1 IMMUNOASSAYS 161
8.8.1.2 CHROMATOGRAPHIC DEVICES 161
8.8.1.3 BREATH ANALYSERS 161
8.8.2 RAPID TESTING DEVICES 161
8.8.2.1 URINE TESTING DEVICES 162
8.8.2.2 ORAL FLUID TESTING DEVICES 162
8.8.2.3 OTHERS 162
8.9 URINALYSIS TESTING PRODUCTS 162
8.9.1 POC URINE STRIP SELF-TESTING 163
8.9.2 POC URINE TEST STRIP PROFESSIONAL TESTING 163
8.10 CHOLESTEROL TESTING PRODUCTS 164
8.10.1 TESTING KITS 164
8.10.2 INSTRUMENTS 165
8.10.2.1 TABLE-TOP ANALYZERS 165
8.10.2.2 HAND-HELD ANALYZERS 165
8.11 TUMOR/CANCER MARKER TESTING PRODUCTS 165
8.12 FECAL OCCULT TESTING PRODUCTS 166
8.12.1 GUAIAC FOB STOOL TEST 167
8.12.2 LATERAL FLOW IMMUNO-FOB TEST 167
8.12.3 IMMUNO-FOB AGGLUTINATION TEST 167
8.12.4 IMMUNO-FOB ELISA TEST 167
8.13 OTHERS 167
 
9 GSA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 168
9.1 OVERVIEW 169
9.2 OTC TESTING 172
9.3 PRESCRIPTION-BASED TESTING 172
10 GSA POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM 173
10.1 OVERVIEW 174
10.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS 177
10.3 IMMUNOASSAYS 177
10.4 DIPSTICKS 177
10.5 MOLECULAR DIAGNOSTICS 177
10.6 CLINICAL CHEMISTRY ASSAYS 178
10.7 MICROFLUIDICS 178
10.8 HEMATOLOGY 178
10.9 OTHERS 178
11 GSA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION 179
11.1 OVERVIEW 180
11.2 BLOOD GLUCOSE 184
11.3 INFECTIOUS DISEASES 185
11.3.1 COVID-19 TESTING 185
11.3.2 HIV TESTING 185
11.3.3 HEPATITIS C TESTING 185
11.3.4 INFLUENZA TESTING 185
11.3.5 TUBERCULOSIS TESTING 185
11.3.6 OTHERS 185
11.4 VITAL SIGN MONITORING 186
11.5 CARDIAC MONITORING 186
11.6 COAGULATION 186
11.7 HAEMATOLOGY 186
11.8 NON- INVASIVE SPO2 MONITORING 186
11.9 BLOOD TRANSFUSION 186
11.10 NON- INVASIVE PCO2 MONITORING 186
11.11 WHOLE BLOOD ANALYSIS 186
11.12 OTHERS 187
 
12 GSA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 188
12.1 OVERVIEW 189
12.2 HOSPITALS 193
12.2.1 PRIVATE 193
12.2.1.1 TIER 1 194
12.2.1.2 TIER 2 194
12.2.1.3 TIER 3 194
12.2.2 PUBLIC 194
12.3 HOME CARE 194
12.4 CLINICS 194
12.5 LABORATORIES 195
12.6 DIAGNOSTIC CENTERS 195
12.7 PATHOLOGY LABS 195
12.8 AMBULATORY SURGERY CENTERS 195
12.9 ELDERLY CARE CENTERS 195
12.10 OTHERS 195
13 GSA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 196
13.1 OVERVIEW 197
13.2 DIRECT TENDER 200
13.3 RETAIL SALES 200
13.4 ONLINE SALES 200
13.5 OTHERS 200
14 BENELUX POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE 201
14.1 OVERVIEW 202
14.2 GLUCOSE MONITORING PRODUCTS 207
14.2.1 STRIPS 208
14.2.2 METERS 208
14.2.3 LANCETS AND LANCING DEVICES 208
14.3 INFECTIOUS DISEASE TESTING PRODUCTS 209
14.3.1 COVID-19 211
14.3.2 HIV TESTING PRODUCTS 211
14.3.2.1 TESTING REAGENTS 211
14.3.2.2 TESTING EQUIPMENT 211
14.3.3 RESPIRATORY INFECTION TESTING PRODUCTS 212
14.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING 212
14.3.5 NAAT-BASED SYSTEMS 212
14.3.6 NON–NAAT-BASED SYSTEMS 212
14.3.7 HEPATITIS C TESTING PRODUCTS 213
14.3.7.1 HCV ANTIBODY TESTS 213
14.3.7.2 HCV VIRAL LOAD TESTS 213
14.3.8 INFLUENZA TESTING PRODUCTS 214
14.3.8.1 TRADITIONAL DIAGNOSTIC TEST 214
14.3.8.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) 215
14.3.8.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT) 215
14.3.8.1.3 VIRAL CULTURE 215
14.3.8.1.4 SEROLOGICAL ASSAY 215
14.3.8.2 MOLECULAR DIAGNOSTIC ASSAY 216
14.3.8.2.1 RT-PCR 217
14.3.8.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP) 217
14.3.8.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT) 217
14.3.8.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA) 217
14.3.9 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING 217
14.3.10 TROPICAL DISEASE TESTING PRODUCTS 217
14.3.11 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 217
14.4 CARDIOMETABOLIC MONITORING PRODUCTS 218
14.4.1 CARDIAC MARKER TESTING PRODUCTS 219
14.4.1.1 HSTNL 220
14.4.1.2 BNP 220
14.4.1.3 D-DIMER 220
14.4.1.4 CK-MB 220
14.4.1.5 MYOGLOBIN 220
14.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 220
14.4.3 BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES 221
14.4.3.1 CARTRIDGES 221
14.4.3.2 REAGENTS 221
14.4.4 BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS 222
14.4.5 PORTABLE 222
14.4.5.1 COMBINED ANALYZERS 223
14.4.5.2 BLOOD GAS ANALYZERS 223
14.4.5.3 ELECTROLYTE ANALYZERS 223
14.4.6 BENCHTOP 223
14.4.6.1 COMBINED ANALYZERS 224
14.4.6.2 BLOOD GAS ANALYZERS 224
14.4.6.3 ELECTROLYTE ANALYZERS 224
14.4.7 HBA1C TESTING PRODUCTS 224
14.4.7.1 HBA1C TESTING INSTRUMENTS 225
14.4.7.2 HBA1C TESTING CONSUMABLES 225
14.4.8 POC ANALYZER 225
14.4.9 ECG DEVICE 225
14.4.9.1 RESTING ECG DEVICES 226
14.4.9.2 STRESS ECG DEVICES 226
14.4.9.3 HOLTER MONITORS 226
14.5 PREGNANCY AND FERTILITY TESTING PRODUCTS 227
14.5.1 PREGNANCY TESTING PRODUCTS 227
14.5.1.1 STRIPS/ DIP STICKS AND CARDS 228
14.5.1.2 MID STREAM DEVICES 228
14.5.1.3 CASSETTES 228
14.5.1.4 DIGITAL DEVICES 228
14.5.1.5 LINE-INDICATOR DEVICES 228
14.5.2 FERTILITY TESTING PRODUCTS 229
14.5.2.1 LUTEINIZING HORMONE (LH) URINE TEST 229
14.5.2.2 FSH TEST 229
14.5.2.3 OTHERS 229
14.6 HAEMATOLOGY TESTING PRODUCTS 230
14.7 COAGULATION MONITORING PRODUCTS 230
14.8 ANTICOAGULATION MONITORING DEVICES 230
14.8.1 PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES 231
14.8.2 ACTIVATED CLOTTING TIME (ACT) 231
14.8.3 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT) 231
14.8.4 PLATELET FUNCTION MONITORING DEVICES 232
14.8.5 VISCOELASTIC COAGULATION MONITORING DEVICES 232
14.8.5.1 ROTATIONAL THROMBOELASTOMETRY (ROTEM) 232
14.8.5.2 THROMBOELASTOGRAPHY (TEG) 232
14.9 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS 233
14.9.1 DOA ANALYSERS 233
14.9.1.1 IMMUNOASSAYS 234
14.9.1.2 CHROMATOGRAPHIC DEVICES 234
14.9.1.3 BREATH ANALYSERS 234
14.9.2 RAPID TESTING DEVICES 235
14.9.2.1 URINE TESTING DEVICES 235
14.9.2.2 ORAL FLUID TESTING DEVICES 235
14.9.3 OTHERS 235
14.10 URINALYSIS TESTING PRODUCTS 236
14.10.1 POC URINE STRIP SELF-TESTING 237
14.10.2 POC URINE TEST STRIP PROFESSIONAL TESTING 237
 
14.11 CHOLESTEROL TESTING PRODUCTS 238
14.11.1 TESTING KITS 238
14.11.2 INSTRUMENTS 239
14.11.2.1 TABLE-TOP ANALYZERS 239
14.11.2.2 HAND-HELD ANALYZERS 239
14.12 TUMOR/CANCER MARKER TESTING PRODUCTS 240
14.13 FECAL OCCULT TESTING PRODUCTS 240
14.13.1 GUAIAC FOB STOOL TEST 241
14.13.2 LATERAL FLOW IMMUNO-FOB TEST 241
14.13.3 IMMUNO-FOB AGGLUTINATION TEST 241
14.13.4 IMMUNO-FOB ELISA TEST 241
14.14 OTHERS 241
15 BENELUX POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM 242
15.1 OVERVIEW 243
15.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS 246
15.3 IMMUNOASSAYS 246
15.4 DIPSTICKS 246
15.5 MOLECULAR DIAGNOSTICS 246
15.6 CLINICAL CHEMISTRY ASSAYS 247
15.7 MICROFLUIDICS 247
15.8 HEMATOLOGY 247
15.9 OTHERS 247
16 BENELUX POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE 248
16.1 OVERVIEW 249
16.2 OTC TESTING 252
16.3 PRESCRIPTION-BASED TESTING 252
17 BENELUX POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION 253
17.1 OVERVIEW 254
17.2 BLOOD GLUCOSE 258
17.3 INFECTIOUS DISEASES 259
17.3.1.1 COVID-19 TESTING 259
17.3.1.2 HIV TESTING 259
17.3.1.3 HEPATITIS C TESTING 259
17.3.1.4 INFLUENZA TESTING 259
17.3.1.5 TUBERCULOSIS TESTING 259
17.3.1.6 OTHERS 259
17.4 VITAL SIGN MONITORING 260
17.5 CARDIAC MONITORING 260
17.6 COAGULATION 260
17.7 HAEMATOLOGY 260
17.8 NON- INVASIVE SPO2 MONITORING 260
17.9 BLOOD TRANSFUSION 260
17.10 NON- INVASIVE PCO2 MONITORING 260
17.11 WHOLE BLOOD ANALYSIS 260
17.12 OTHERS 261
18 BENELUX POINT-OF-CARE TESTING (POCT) MARKET, BY END USER 262
18.1 OVERVIEW 263
18.2 HOSPITALS 267
18.2.1 PRIVATE 268
18.2.1.1 TIER 1 268
18.2.1.2 TIER 2 268
18.2.1.3 TIER 3 268
18.2.2 PUBLIC 268
18.3 HOME CARE 269
18.4 CLINICS 269
18.5 LABORATORIES 269
18.6 DIAGNOSTIC CENTERS 269
18.7 PATHOLOGY LABS 269
18.8 AMBULATORY SURGERY CENTERS 269
18.9 ELDERLY CARE CENTERS 269
18.10 OTHERS 269
19 BENELUX POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL 270
19.1 OVERVIEW 271
19.2 DIRECT TENDER 274
19.3 RETAIL SALES 274
19.4 ONLINE SALES 274
19.5 OTHERS 274
20 GSA & BENELUX 275
20.1 GERMANY 282
20.2 NETHERLANDS 310
20.3 SWITZERLAND 337
20.4 BELGIUM 362
20.5 AUSTRIA 387
20.6 LUXEMBOURG 413
21 GSA AND BENELUX POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY LANDSCAPE 438
21.1 COMPANY SHARE ANALYSIS: GSA AND BENELUX 438
22 SWOT ANALYSIS 439
23 COMPANY PROFILE 440
23.1 F. HOFFMANN-LA ROCHE LTD 440
23.1.1 COMPANY SNAPSHOT 440
23.1.2 REVENUE ANALYSIS 440
23.1.3 PRODUCT PORTFOLIO 441
23.1.4 RECENT DEVELOPMENT 441
23.2 DANAHER CORPORATION 442
23.2.1 COMPANY SNAPSHOT 442
23.2.2 REVENUE ANALYSIS 442
23.2.3 PRODUCT PORTFOLIO 443
23.2.4 RECENT DEVELOPMENT 443
23.3 SIEMENS HEALTHINEERS AG 444
23.3.1 COMPANY SNAPSHOT 444
23.3.2 REVENUE ANALYSIS 444
23.3.3 PRODUCT PORTFOLIO 445
23.3.4 RECENT DEVELOPMENT 445
23.4 BIO- RAD LABORATORIES, INC. 446
23.4.1 COMPANY SNAPSHOT 446
23.4.2 REVENUE ANALYSIS 446
23.4.3 PRODUCT PORTFOLIO 447
23.4.4 RECENT DEVELOPMENT 447
23.5 BIOMERIEUX 449
23.5.1 COMPANY SNAPSHOT 449
23.5.2 REVENUE ANALYSIS 449
23.5.3 PRODUCT PORTFOLIO 450
23.5.4 RECENT DEVELOPMENT 450
23.6 ACCUBIOTECH CO., LTD. 451
23.6.1 COMPANY SNAPSHOT 451
23.6.2 PRODUCT PORTFOLIO 451
23.6.3 RECENT DEVELOPMENT 459
 
23.7 ABBOTT 460
23.7.1 COMPANY SNAPSHOT 460
23.7.2 REVENUE ANALYSIS 460
23.7.3 PRODUCT PORTFOLIO 461
23.7.4 RECENT DEVELOPMENT/NEWS 461
23.8 BINX HEALTH 462
23.8.1 COMPANY SNAPSHOT 462
23.8.2 SOLUTION PORTFOLIO 462
23.8.3 RECENT DEVELOPMENT 463
23.9 BD 464
23.9.1 COMPANY SNAPSHOT 464
23.9.2 REVENUE ANALYSIS 464
23.9.3 PRODUCT PORTFOLIO 465
23.9.4 RECENT DEVELOPMENT/NEWS 466
23.10 EKF DIAGNOSTICS HOLDINGS PLC 467
23.10.1 COMPANY SNAPSHOT 467
23.10.2 REVENUE ANALYSIS 467
23.10.3 PRODUCT PORTFOLIO 468
23.10.4 RECENT DEVELOPMENT 470
23.11 HOLOGIC, INC 471
23.11.1 COMPANY SNAPSHOT 471
23.11.2 REVENUE ANALYSIS 471
23.11.3 PRODUCT PORTFOLIO 472
23.11.4 RECENT DEVELOPMENT 473
23.12 MERIDIAN BIOSCIENCE, INC. 474
23.12.1 COMPANY SNAPSHOT 474
23.12.2 PRODUCT PORTFOLIO 474
23.12.3 RECENT DEVELOPMENT/NEWS 477
23.13 QIAGEN 478
23.13.1 COMPANY SNAPSHOT 478
23.13.2 REVENUE ANALYSIS 478
23.13.3 PRODUCT PORTFOLIO 479
23.13.4 RECENT DEVELOPMENT 479
23.14 QUIDELORTHO CORPORATION 480
23.14.1 COMPANY SNAPSHOT 480
23.14.2 REVENUE ANALYSIS 480
23.14.3 PRODUCT PORTFOLIO 481
23.14.4 RECENT DEVELOPMENT 483
 
23.15 SEKISUI DIAGNOSTICS 484
23.15.1 COMPANY SNAPSHOT 484
23.15.2 PRODUCT PORTFOLIO 484
23.15.3 RECENT DEVELOPMENT 485
23.16 SYSMEX CORPORATION 486
23.16.1 COMPANY SNAPSHOT 486
23.16.2 REVENUE ANALYSIS 486
23.16.3 PRODUCT PORTFOLIO 487
23.16.4 RECENT DEVELOPMENT 489
23.17 SIENCO, INC. 490
23.17.1 COMPANY SNAPSHOT 490
23.17.2 PRODUCT PORTFOLIO 490
23.17.3 RECENT DEVELOPMENT 491
23.18 TRINITY BIOTECH 492
23.18.1 COMPANY SNAPSHOT 492
23.18.2 REVENUE ANALYSIS 492
23.18.3 PRODUCT PORTFOLIO 493
23.18.4 RECENT DEVELOPMENT 493
23.19 THERMO FISHER SCIENTIFIC INC. 494
23.19.1 COMPANY SNAPSHOT 494
23.19.2 REVENUE ANALYSIS 494
23.19.3 PRODUCT PORTFOLIO 495
23.19.4 RECENT DEVELOPMENT 495
23.20 WERFEN 496
23.20.1 COMPANY SNAPSHOT 496
23.20.2 PRODUCT PORTFOLIO 496
23.20.3 RECENT DEVELOPMENT 498
24 QUESTIONNAIRE 499